Publications and Presentations


Cullen J et al. Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade. Journal for ImmunoTherapy of Cancer; April 2024

Brown G et al. Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate. Frontiers in Veterinary Science, 26 October 2022

De Ridder T et al. Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours. Frontiers in Veterinary Science, 15 December 2021

Brown G et al. Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate. Frontiers in Veterinary Science, 27 August 2021

Cullen J et al. The activation of PKC and impact on anticancer activity of tigilanol tiglate and associated expoxytiglianes. Scientific reports, January 2021

Reddell P et al. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate. Journal of veterinary internal medicine, January 2021

Jones P et al. Recurrence‐free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate. Journal of veterinary internal medicine, January 2021

De Ridder T et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC -46). Journal of Veterinary Internal Medicine, January 2021

Moses R. et al. Novel epoxy-tiglianes stimulate skin keratinocyte wound healing responses and re-epithelialization via protein kinase C activation. Biochemical Pharmacology, May 2020

Hansen N et al. Progressive cutaneous viral pigmented plaques in three Hungarian Vizslas and the response of the lesions to topical tigilanol tiglate gel. Veterinary Medicine and Science, 2018

Panizza BJ et al. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). EBioMedicine, December 2019

Miller J et al. Dose characterization of the investigational anticancer drug Tigilanol Tiglate (EBC-46) in the local treatment of canine mast cell tumors. Frontiers in Veterinary Science, Volume 6, Article 106, April 2019

Barnett C, et al. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate. Investigational New Drugs; April 2018

Boyle G, et al. Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models, PLoS ONE 2014, Vol 9 Issue 10, e108887

Grant EL et al. Floral and reproductive biology of the medicinally significant rainforest tree, Fontainea picrosperma (Euphorbiaceae) Industrial Crops & Products 2017, 108:416-422

Scientific presentations